[A19-57] Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.10.2019
Commission awarded on 11.07.2019 by the Federal Joint Committee (G-BA).
Monotherapy of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer
Without prior chemotherapy for metastatic breast cancer: indication of considerable added benefit; with prior chemotherapy for metastatic breast cancer: hint of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.